Compare Ross Stores, Inc. (ROST) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Summit Therapeutics Inc — how do they compare? Ross Stores, Inc. trades at $222.86 (market cap $71.94B), while Summit Therapeutics Inc trades at $17.44 (market cap $13.71B). The key difference: Ross Stores, Inc. is far larger — about 5.2× Summit Therapeutics Inc's market cap, and Ross Stores, Inc. pays a 0.79% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ross Stores, Inc. for 48 Days and Summit Therapeutics Inc for 16 Days on average.
| ROST | SMMT | |
|---|---|---|
Market Cap | $71.94B | $13.71B |
Volume | 2,002,519 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $255.23 | $26.38 |
52-Week Low | $147.71 | $12.43 |
Typical Hold Time | 48 Days | 16 Days |
Enterprise Value | $72.39B | $13.04B |
Dividend Yield | 0.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $222.41, down 1.38% amid broader market weakness. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability metrics including 42.63% ROE and 10.85% net margin. Technical indicators signal bearish momentum with the price near key support at $221, while analyst consensus remains bullish with a $274.14 price target. Recent news highlights store expansion initiatives and strong closeout supply positioning the company for growth.
ROST presents a compelling investment case with strong operational performance and analyst confidence, though near-term technical weakness and competitive pressures warrant caution. The 16% upside to consensus target offers potential reward, but investors should monitor execution of expansion plans and consumer spending trends given the bearish technical signals.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
